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Background: Molecular analysis of sputum provides a promising approach for lung cancer diagnosis, yet is limited
by the difficulty in collecting the specimens from individuals who can’t spontaneously expectorate sputum. Lung
Flute is a small self-powered audio device that can induce sputum by generating sound waves and vibrating in the
airways of the lungs. Here we propose to evaluate the usefulness of Lung Flute for sputum sampling to assist
diagnosis of lung cancer.
Methods: Forty-three stage I lung cancer patients and 47 cancer-free individuals who couldn’t spontaneously
cough sputum were instructed to use Lung Flute for sputum sampling. Expressions of two microRNAs, miRs-31 and
210, were determined in the specimens by qRT-PCR. The results were compared with sputum cytology.
Results: Sputum was easily collected from 39 of 43 (90.7%) lung cancer patients and 42 of 47 (89.4%) controls with
volume ranges from 1 to 5 ml (median, 2.6 ml). The specimens had less than 4% oral squamous cells, indicating
that sputum was obtained from low respiratory tract. Expressions of miRs-31 and 210 in sputum were considerably
higher in cancer patients than cancer-free individuals (8.990 vs. 4.514; 0.6847 vs. 0.3317; all P <0.001). Combined use
of the two miRNAs produced a significantly higher sensitivity (61.5% vs. 35.9%, P = 0.002) and a slightly lower
specificity (90.5% vs. 95.2%, p = 0.03) compared with cytology for lung cancer diagnosis.
Conclusion: Lung Flute could potentially be useful in convenient and efficient collection of sputum for molecular
diagnosis of lung cancer.
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Lung cancer is the leading cause of cancer death in men
and women. Non-small cell lung cancer (NSCLC) is the
most common type of lung cancer, mainly consisting of
adenocarcinomas (AC) and squamous cell carcinomas
(SCC). The early detection of NSCLC followed by
appropriate treatments will reduce the mortality [1].
Low-dose CT scan to screen for lung cancer in heavy
smokers can reduce the death rate from the malignancy
by 20% over chest X-rays [2]. However, CT screening
has only 61% specificity over the 3-year screening period
[2]. The low specificity often results in anxiety, unneces-
sary biopsies, and surgeries that carry their own risks to
many smokers who have benign diseases. Noninvasive* Correspondence: fjiang@som.umaryland.edu
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in any medium, provided the original work is papproaches that can help diagnose early stage lung can-
cer are urgently desired.
Sputum is a noninvasively accessible body fluid that
contains exfoliated bronchial epithelial cells [3]. Sputum
cytology can identify morphological abnormalities of
bronchial epitheliums. However, it has a poor sensitivity
[4]. Molecular study of sputum could detect the cells
containing lung tumor-associated molecular aberrations
that occur in microscopically normal appearing epithe-
liums, thus providing a promising approach for diagnosis
of lung cancer [5-7]. For instance, p16 hypermethylation
was found in sputum collected from patients with lung
cancer 5–35 months before cytological and clinical diag-
noses [8]. Analysis of numerical chromosome changes
could predict lung cancer 18 months before clinical
diagnosis [9]. Quantification of microRNA (miRNA)
expression in clinical specimens could offer a novel ap-
proach for cancer screening and early detection [10-13].is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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stably present in sputum and reliably measurable by
using quantitative reverse transcriptase PCR (qRT-PCR)
assay [14-16]. We further analyzed 12 lung cancer-
associated miRNAs in sputum and compared with CT
scan for diagnosis of lung cancer in 66 lung cancer
patients and 68 cancer-free control subjects. We found
that two miRNAs (miR-31 and miR-210) when used in
combination produced 65.2% sensitivity and 89.7% speci-
ficity. Notably, integrating the sputum miRNA bio-
markers and CT yielded a significant higher specificity
than CT used alone (91.2% vs. 83.8%, P < 0.05). There-
fore, the assessment of miRNAs in sputum might be
useful to augment CT, particularly increase its specifi-
city, for the early detection of lung cancer.
However, very often some subjects are not able to
spontaneously expectorate sputum. Alternately, sputum
induction with inhalation of hypertonic saline mist has
been used to obtain adequate sputum samples [17,18].
Yet the approach is limited by laborious and time con-
suming, need for specialized equipment, and the risk of
bronchospasm and respiratory inflammation. Therefore,
there is an unmet need to develop a safe, simple, and ef-
ficient means for efficiently and safely collecting sputum.
Lung Flute is a small self-powered audio device
consisting of a mouthpiece and a reed inside a 36.8-cm
rectangular plastic tube [19]. Lung Flute can create
sound with a frequency of 18–22 Hz [19]. This sound
wave, when generated at the mouth by mild exhalation,
could vibrate in the airways and cilia. The produced
sound resonates with the natural frequency and aug-
ments mucus clearing system in the airways, and hence
makes mucus secretions thinner and more easily ex-
pelled by coughing. Previously, Fujita et al. found that
Lung Flute could efficiently induce sputum from tra-
cheobronchial and low respiratory track [19]. Further-
more, the sputum samples collected by using this
technique had no significant differences in biological
markers or cell counts compared with those induced
using hypertonic saline in patients with chronic bron-
chitis. In addition, Fujita et al. [19] suggested that al-
though Lung Flute depends on patient effort, it was
noninvasive and easy to use. The device did not require
special equipment, and the patient didn’t have an empty
stomach before using it. Patients could easily carry the
device and use it at home repetitively [19]. Moreover,
the use of Lung Flute for sputum sampling could help
rapidly diagnose pulmonary tuberculosis [19]. However,
there has no report of investigating its utility in
collecting sputum for diagnosis of lung cancer.
The goals of the study were to evaluate whether 1) the
use of Lung Flute could safely and effectively collect
sputum from lung cancer patients and cancer-free indi-
viduals who were not able to spontaneously producesputum, and whether 2) analysis of miRNAs in the spu-
tum samples might facilitate diagnosis of lung cancer.
Methods
Patients and sample collection and preparation
Eligible lung cancer patients were stage I NSCLC pa-
tients before the patients receiving surgical treatment,
preoperative adjuvant chemotherapy and radiotherapy.
The research protocol for the study was approved by
Institutional Review Board of University of Maryland
Medical Center. Inclusion criteria for cancer-free con-
trols were individuals who had no a history of cancer in
the last 3 years at the time of enrolment. Furthermore,
enrollment was restricted to lung cancer cases and
controls who were not able to expectorate spontaneous
sputum. Exclusion criteria for both cancer and cancer-
free patients were 1) exacerbation of chronic obstructive
pulmonary disease (COPD) or hospitalization for COPD
within 8 weeks prior to enrollment, 2) predominant
asthma and bronchiectasis by clinical assessment, 3)
history of cough syncope, 4) pregnant or nursing women,
and 5) inability to comply with study procedures. Written
informed consent for participation was obtained through
an institutional review board-approved protocol. Final
diagnosis for lung cancer was made with histopathologic
examinations of specimens obtained by CT-guided trans-
thoracic needle biopsy, transbronchial biopsy, videotape-
assisted thoracoscopic surgery, or surgical resection. The
surgical pathologic staging was determined according to
the TNM classification of the International Union Against
Cancer with the American Joint Committee on Cancer
and the International Staging System for Lung Cancer.
Histopathological classification was determined according
to the World Health Organization classification. The
diagnosis of COPD was established according to the
standards of the Global Initiative for Chronic Obstruct-
ive Lung Disease [20].
Sputum was collected by using Lung Flute (Medical
Acoustics, Buffalo, NY) according to the manufacturer’s
instruction and the method previously described [19].
Briefly, after blowing nose and rinsing mouth to minimize
contamination of squamous cells from postnasal drip and
saliva, the participants placed lips around mouthpiece.
They blew out fast and hard through Lung Flute. After
taking a quick breath, the participants blew out again, and
then coughed up sputum into a sterile container. The
samples were processed on ice in four volumes of 0.1%
dithiothreitol (Sigma-Aldrich Corporation, Saint Louis,
MO), and the mixture was vortexed for 15 min. A double
volume of a phosphate-buffered saline solution was then
added, and the mixture was briefly vortexed. After filtra-
tion through two layers of a sterile gauze to remove
mucous and debris, sputum was centrifuged for 10 min at
800 g. The cell pellet was resuspended in a phosphate-
Table 1 Demographic and clinical data of lung cancer







Total no. 39 42
Age, years 65.6 62.3
7.8 8.4
Gender
Men 23 58.9 26 60.5
Women 16 41.1 16 39.5
Race
White American 29 74.4 31 73.8
African American 10 25.6 11 26.2




Squamous cell carcinoma 18 46.1
All are stage I NSCLC
Abbreviation: NSCLC non-small cell lung cancer.
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performed using slides stained with the May-Grünwald-
Giemsa method. The sputum specimens were of low re-
spiratory origin as indicated by the presence of less than
4% oral squamous cells. Slides were considered insuffi-
cient for diagnosis, if they had zero to three histiocytes,
excessive cellular degeneration, or obscuring bacterial and
fungal contaminations.
Cytology
Cytocentrifuge slides were prepared from each sputum
sample by using a cytospin machine (Shandon, Inc.,
Pittsburgh, PA). The slides were then fixed in 95% alco-
hol for Papanicolaou’s staining [21]. Cytologic diagnosis
was performed based on a seven-tiered scoring system
as follows: negative, squamous metaplasia, mild dyspla-
sia, moderate dysplasia, severe dysplasia, carcinoma, or
insufficient for diagnosis. Positive cytology included se-
vere dysplasia and carcinoma [21,22].
Isolation of RNA and analysis of miRNAs by qRT-PCR
Total RNA containing small RNA was extracted from
sputum as previously described [14]. The purity and
concentration of RNA were determined from OD260/
280 readings using a dual beam UV spectrophotometer
(Eppendorf AG, Hamburg, Germany). RNA integrity was
determined by capillary electrophoresis using the RNA
6000 Nano Lab-on-a-Chip kit and the Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA).
miRs-31 and 210, which were previously identified as
potential sputum miRNA biomarkers [14-16], were evalu-
ated in the sputum specimens by using qRT-PCR with
Taqman miRNA assays (Applied Biosystems, Foster City,
CA) [14-16]. Briefly, RNA was applied for reverse tran-
scription (RT) by using the Applied Biosystems 9700
Thermocycler (Applied Biosystems) with miRNA-specific
looped primer and TaqMan® MicroRNA RT Kit (Applied
Biosystems). The reaction includes 50 nM stem-loop
RT primers, 1× RT buffer, 0.25 mM each of dNTPs,
and 3.33 U/μl MultiScribe reverse transcriptase in a
total volume of 15 μL. The 20 μl PCR reaction included
RT product, 1× TaqMan® Universal PCR Master Mix
(Applied Biosystems), and the corresponding primers
and Taqman probes for the target genes. The reactions
were incubated in a 94-well plate at 95°C for 15 min,
followed by 45 cycles of 95°C for 15 s and 60°C for 1 min.
Threshold cycle (Ct) values of the miRNAs were normal-
ized in relation to that of U6. All assays were performed in
triplicates, and one no-template control and two interplate
controls were carried along in each experiment.
Statistical analysis
Pearson’s correlation coefficient tests with multivariate
regression analysis were performed to evaluate theassociations between expressions of the miRNAs and clin-
icopathologic and demographic characteristics. Receiver-
operating characteristic (ROC) analysis was undertaken
using expression level for each miRNA in lung cancer pa-
tients and cancer-free controls [23]. The cut-off value was
chosen at the point of highest Youden Index for each
miRNA from the ROC in the set of cases and controls. All
P values were two sided, and a P value of <0.05 was con-
sidered statistically significant.
Results
Collecting sputum by using lung flute
Fourty-three lung cancer cases and 47 controls with
COPD who were not able to spontaneously cough spu-
tum were recruited in the current study. Sputum was
collected by using Lung Flute from 39 of the 43 (90.7%)
lung cancer patients and 42 of the 47 (89.4%) cancer-
free controls. Characteristics of the 39 lung cancer
patients and 42 cancer-free individuals are shown in
Table 1. The lung cancer patients are diagnosed with
stage I NSCLC. Of the 39 NSCLC patients, 21 are classi-
fied with AC and 18 with SCC. The age of the lung can-
cer cases is 65.6 ± 7.8 year old and 23 (58.9%) are males.
The number of smoking pack-years of the lung cancer
cases is 48.5 ± 35.3. Of the lung cancer patients, there
are 36 (92.3%) smokers with >30 pack-years with COPD,
and three non-smokers. The 42 cancer-free subjects in-
clude 38 (90.5%) with COPD, one with pneumonia, two
with sarcoidosis, and one with inflammatory granuloma.
The cancer-free subjects consist of 26 males (60.5%).
Figure 1 The expression levels of two miRNAs, miRs-31 and 210, were assessed in sputum of 39 stage I NSCLC patients and 42 cancer-
free individuals using qRT-PCR. U6 small nuclear RNA was used as an internal control.
Table 2 The AUCs and corresponding sensitivity and
specificity of the two miRNAs that display different
expression betwee lung cancer patients and controls




miR-31 <0.001 0.785 0.6847 to 0.8855 0.05119
miR-210 <0.001 0.767 0.6662 to 0.8676 0.05136
Combined use of miR-31
and 210
<0.001 0.826 0.7366 to 0.9154 0.04559
Abbreviations: AUC the area under receiver operating characteristic curve,
CI confidence interval.
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The number of smoking pack-years of the control sub-
jects is 46.7 ± 32.8. Of the 42 cancer-free subjects, there
are 38 smokers with >30 pack-years, and four non-
smokers.
The individuals could expectorate sputum within
20 minutes after using Lung Flute. The median volume
of the sputum sample was 2.6 ml, ranging from 1.0 to
5.0 ml. There was not statistical difference of the success
rate of the collection and volume of the specimens re-
garding smoking status, diagnosis of lung cancer, and
pulmonary function. There were no statistical differences
of differential cell count between the lung cancer pa-
tients and cancer-free controls (P > 0.05) (Additional file 1:
Table S1). Side effects of using Lung Flute include 8.6%
(7 of 81) individuals complained of minor sore throat or
dizziness. However, the slight discomforts could be re-
duced by drinking water and taking several slow breaths.
Expressions of the miRNAs in lung flute collected-sputum
and the diagnostic significance for lung cancer
Expressions of the two miRNAs, miRs-31 and 210, were
successfully measured in sputum by using qRT-PCR
assay that always yielded a ≤32 Ct value for each
miRNA gene. As shown in Figure 1, miR-31 and miR-
210 exhibited higher expression levels in sputum of
stage I lung cancer patients compared to cancer-free
subjects (8.990 vs. 4.514; 0.6847 vs. 0.3317, respectively;
all P <0.001). Furthermore, the expression levels in spu-
tum were positively associated with smoking history of
lung cancer patients (P = 0.032 and 0.026, respectively).
However, there was no statistically significant correl-
ation of the changes of the miRNAs with age, ethnicity,
and histological type of lung cancer (All p > 0.05).
The two miRNAs exhibited area under the ROC curve
(AUC) values of 0.785 and 0.767 in distinguishing lung
cancer cases from control subjects, respectively (Table 2)
(Figure 2). Interestingly, combined use of the two
miRNAs produced 0.826 AUC, offering superior per-
formance compared to any of the two miRNAs used
alone (All P < 0.05) (Table 2) (Figure 2). As a result,combined analysis of the two miRNAs generated 61.5%
sensitivity and 90.5% specificity for diagnosis of lung
cancer.Comparison of sputum cytology and analysis of miRNAs
for lung cancer diagnosis
Cytologic diagnoses of squamous metaplasia and mild,
moderate, severe dysplasia, and carcinoma were signifi-
cantly associated with lung cancer status (Additional file 2:
Table S2). For instance, of 42 patients without cancer, 22
(52.4%) were negative by cytology. Conversely, of 39
lung cancer patients, only three (7.7%) were negative by
cytology. Furthermore, a diagnosis of severe dysplasia
or carcinoma was associated with cancer in 14 lung
cancer cases, whereas a diagnosis of severe dysplasia or
carcinoma was found in only two patients without lung
cancer. If severe dysplasia or carcinoma was considered
to be the predictors of the presence of lung cancer, the
sensitivity and specificity of the cytological examination
of the sputum samples was 35.9% and 95.2%, respect-
ively. When compared with analysis of the miRNAs in
the samples, cytology had a considerably lower sensitiv-
ity for lung cancer diagnosis (35.9% vs. 61.5%, p < 0.01)
(Figure 3). However, analysis of the miRNAs displayed
a lower specificity compared with sputum cytology
(90.5% vs. 95.2%, P = 0.003) (Figure 3). Interestingly, in-
tegrating the analysis of the miRNAs with cytology of-
fered a higher sensitivity than did any single approach
Figure 2 Receiver-operator characteristic (ROC) curve analysis of expression levels of the two miRNAs (miR-31 and miR-210) in sputum
of 39 patients diagnosed with stage I NSCLC and 42 cancer-free individuals. miR-31 and miR-210 produce 0.785-0.767 AUC values (A-B),
being significantly lower than 0.826 AUC created from combined use of two miRNAs (C) (P < 0.05).
Figure 3 Comparison of miRNA biomarkers and sputum
cytology for lung cancer diagnosis in 39 patients diagnosed
with stage I NSCLC and 42 cancer-free individuals. Analysis of
the two miRNAs (miR-31 and miR-210) in sputum produces a higher
specificity, a lower specificity compared with sputum cytology.
Combined analysis of the miRNAs and cytology presents a higher
sensitivity compared with a single approach, maintaining a high
specificity at 93.0%. *, statistical significance (P < 0.05).
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while having 93.0% specificity (Figure 3).
Discussion
In the present study, we demonstrate that the success
rate of sputum sampling is approximately 90%, similar
to the reported rate [17] of sputum induction by inhal-
ation of hypertonic saline. The median volume of the
sputum samples collected by Lung Flute is 2.6 ml.
Sputum is of low respiratory origin as indicated by the
presence of less than 4% oral squamous cells. Therefore,
the use of Lung Flute can collect sputum with appropri-
ate amount and quality for cytological and molecular
studies. Furthermore, the success rate of sputum sam-
pling by using Lung Flute and sample volume don’t dis-
play significant difference between smokers and
nonsmokers, and are not associated with numbers of
pack years as well. The parameters are also not associ-
ated with pulmonary function status of the participants.
In addition, the small device is user-friendly, because
only minor discomforts, such as dizziness and sore throat,
are observed in a small percentage of participants. The
slight discomforts could easily be remedied. There is no
major adverse effect, including bronchoconstriction and
respiratory inflammation in the participants when using
Lung Flute. Taken together, the findings from our present
study reveal that the use of Lung Flute could safely and ef-
fectively collect sputum from lung cancer patients and
cancer-free individuals who were not able to spontan-
eously produce sputum.
Our study also shows that the assessment of the
miRNAs in Lung Flute-collected sputum produces a
higher sensitivity compared with conventional sputum
cytology. Furthermore, combined use of the miRNA
biomarkers and cytological analysis in the sputumspecimens has synergetic efficiency for diagnosis of lung
cancer demonstrated by a considerably higher sensitivity
compared with each approach used alone. Therefore, the
small device could provide a potential tool to facilitate
diagnosis of lung cancer through analysis of sputum.
The Lung Flute-collected sputum specimens might also
have the potential to be used for studying other forms of
biomarkers in the early detection of lung cancer. For ex-
ample, methylations and mutations of lung cancer-
related genes could be examined by PCR, or genomic
aberrations of lung cancer-related genes by fluorescence
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undertake a project to compare performance character-
istics of the miRNAs to that of the previously developed
biomarkers using Lung Flute-obtained sputum speci-
mens. We are carrying out a study in a large population-
based case–control study to validate the performance of
Lung Flute, compare the efficiency between Lung Flute
and sputum induction with inhalation of hypertonic
saline mist, and evaluate the contraindication to the
Lung Flute.
Conclusions
Our study indicates that the use of Lung Flute can
conveniently and efficiently obtain appropriate sputum
from low reparatory track of individuals who are not
able to expectorate spontaneous sputum. The applica-
tion of the small device might overcome a major obs-
tacle of applying cytological and molecular analyses of
sputum for lung cancer early detection and screening.
However, the diagnostic value using Lung Flute for lung
cancer should be validated in independent and prospect-
ive case-controlled cohort studies.
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cancer-free individuals*.
Additional file 2: Table S2. Cytologic diagnosis in lung cancer patients
and cancer-free controls.
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